$0.55
5.66% today
Nasdaq, Apr 03, 06:16 pm CET
ISIN
US00444T1007
Symbol
TLPH
Sector
Industry

AcelRx Pharmaceuticals, Inc. Stock price

$0.58
+0.04 7.96% 1M
-0.23 28.02% 6M
+0.06 11.24% YTD
-0.40 40.63% 1Y
-5.22 89.94% 3Y
-21.02 97.30% 5Y
-79.62 99.27% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.05 10.00%
ISIN
US00444T1007
Symbol
TLPH
Sector
Industry

Key metrics

Market capitalization $9.97m
Enterprise Value $1.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.24
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-15.25m
Free Cash Flow (TTM) Free Cash Flow $-12.68m
Cash position $8.86m
EPS (TTM) EPS $-0.51
P/E forward negative
Short interest 0.70%
Show more

Is AcelRx Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

AcelRx Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from AcelRx Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.53 8.53
26% 26%
-
- Research and Development Expense 6.72 6.72
31% 31%
-
-15 -15
7% 7%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
10% 10%
-
Net Profit -13 -13
29% 29%
-

In millions USD.

Don't miss a Thing! We will send you all news about AcelRx Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AcelRx Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
3 days ago
Talphera, Inc. (NASDAQ:TLPH ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Shakil Aslam - CMO Conference Call Participants Thomas Yip - H.C. Wainwright Naz Rahman - Maxim Group Operator Welcome to the Talphera Fourth Quarter and Full Year 2024 Financial Results Conference call.
Neutral
PRNewsWire
3 days ago
The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 Talphera expects the registrational NEPHRO CRRT study to be completed by the end of 2025 Cash and investments at December 31, 2024 of $8.9 million, together with the private placement financing recently announced of up to $14.8 million, expected to provide capital through ...
Neutral
PRNewsWire
3 days ago
The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 patients, of which 6 patients are already enrolled Talphera believes the NEPHRO CRRT study should be completed by the end of 2025 Existing investors, Nantahala Capital and Rosalind Advisors led the capital commitment priced at-the-market as defined by Nasdaq rules $4.925 m...
More AcelRx Pharmaceuticals, Inc. News

Company Profile

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Head office United States
CEO Vincent Angotti
Employees 13
Founded 2005
Website talphera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today